MedTrace Logo

A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors

NCT07223125 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to determine safe and effective dose (recommended phase 2 doses \[RP2Ds\]) of JNJ-89862175 in Part 1 (dose escalation), and to further evaluate how safe JNJ-89862175 is at the RP2Ds in Part 2 (dose expansion) in participants with advanced stage solid tumors.

Conditions

  • Advanced-stage Solid Tumors

Interventions

DRUG

JNJ-89862175

JNJ-89862175 will be administered.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2026-12-15
Completion
2028-08-15
FDA Drug
Yes

Countries

  • United States
  • France
  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07223125 on ClinicalTrials.gov